Inhibition of the progesterone nuclear receptor during the bone linear growth phase increases peak bone mass in female mice

Area of Science:

• Endocrinology
• Bone Biology
• Pharmacology

Background:

• Peak bone mass (PBM) augmentation is key to preventing osteoporosis.
• Current treatments to increase PBM are limited.
• Progesterone signaling's role in bone acquisition requires further elucidation.

Purpose of the Study:

• To investigate if inhibiting the nuclear progesterone receptor (nPR) can enhance PBM.
• To evaluate the effects of nPR knockout and nPR antagonist administration on bone mass.

Main Methods:

• Comparison of bone mass in female progesterone nuclear receptor knockout (PRKO) mice and wild-type (WT) littermates.
• Administration of the nPR antagonist RU486 to female WT mice during the bone growth period (1-3 months).
• Analysis of cancellous and cortical bone mass in the distal femurs.

Main Results:

• Female PRKO mice exhibited significantly higher cancellous and cortical bone mass compared to WT controls.
• Increased bone formation was observed in female PRKO mice.
• RU486 administration partially replicated the high bone mass phenotype in WT mice.

Conclusions:

• Inhibition of nPR during the critical bone growth phase (1-3 months) promotes osteogenesis.
• This leads to the acquisition of higher peak bone mass.
• nPR inhibition represents a novel therapeutic approach for augmenting bone mass and potentially reducing osteoporosis burden.